Literature DB >> 8837611

DNA-based immunization by in vivo transfection of dendritic cells.

C Condon1, S C Watkins, C M Celluzzi, K Thompson, L D Falo.   

Abstract

Delivery of antigen in a manner that induces effective, antigen-specific immunity is a critical challenge in vaccine design. Optimal antigen presentation is mediated by professional antigen-presenting cells (APCs) capable of taking up, processing and presenting antigen to T cells in the context of costimulatory signals required for T-cell activation. Developing immunization strategies to optimize antigen presentation by dendritic cells, the most potent APCs, is a rational approach to vaccine design. Here we show that cutaneous genetic immunization with naked DNA results in potent, antigen-specific, cytotoxic T lymphocyte-mediated protective tumor immunity. This method of immunization results in the transfection of skin-derived dendritic cells, which localize in the draining lymph nodes. These observations provide a basis for further development of DNA-based vaccines and demonstrate the feasibility of genetically engineering dendritic cells in vivo.

Mesh:

Substances:

Year:  1996        PMID: 8837611     DOI: 10.1038/nm1096-1122

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  161 in total

1.  Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Authors:  D E Hassett; J Zhang; M Slifka; J L Whitton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Intralymphatic immunization enhances DNA vaccination.

Authors:  K J Maloy; I Erdmann; V Basch; S Sierro; T A Kramps; R M Zinkernagel; S Oehen; T M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 3.  Strategies for improving responses to DNA vaccines.

Authors:  J S Boyle; I G Barr; A M Lew
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

Review 4.  RNA-transfected dendritic cells in cancer immunotherapy.

Authors:  D A Mitchell; S K Nair
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 5.  Activation of skin dendritic cells by immunostimulatory DNA.

Authors:  J C Vogel; M C Udey
Journal:  Springer Semin Immunopathol       Date:  2000

Review 6.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

7.  Dendritic cells can initiate protective immune responses against malaria.

Authors:  O Bruña-Romero; A Rodriguez
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

8.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 9.  Dendritic cell delivery of plasmid DNA. Applications for controlled genetic immunization.

Authors:  R J Mumper; H C Ledebur
Journal:  Mol Biotechnol       Date:  2001-09       Impact factor: 2.695

Review 10.  Immunotherapy of melanoma.

Authors:  C Smith; V Cerundolo
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.